Literature DB >> 19631712

Platelet derived growth factor BB is a ligand for dermatan sulfate chain(s) of small matrix proteoglycans from normal and fibrosis affected fascia.

Ewa M Koźma1, Grzegorz Wisowski, Krystyna Olczyk.   

Abstract

Structural requirements of the short isoform of platelet derived growth factor BB (PDGF-BB) to bind dermatan sulfate (DS)/chondroitin sulfate (CS) are unknown. Meanwhile the interaction may be important for tissue repair and fibrosis which involve both high activity of PDGF-BB and matrix accumulation of DS. We examined by the solid phase assay the growth factor binding to DS chains of small proteoglycans from various fasciae as well as to standard CSs. Before the assay a structural analysis of DSs and CSs was accomplished involving the evaluation of their epimerization and/or sulfation patterns. In addition, in vivo acceptors for PDGF-BB in fibrosis affected fascia were detected. PDGF-BB binding sites on DSs/CSs are located in long chain sections with the same type of hexuronate isomer however without any apparent preference to glucuronate or iduronate residues. Alternatively, the interaction seems to involve two shorter DS chain sections assembling disaccharides with the same type of hexuronate isomer which are separated by disaccharide(s) with another hexuronate one. Moreover, DS/CS affinity to the growth factor most probably depends on an accumulation of di-2,4-O-sulfated disaccharides in binding site while the presence of 6-O-sulfated N-acetyl-galactosamine residues rather attenuates the binding. All examined fascia DSs and standard CSs showed significant PDGF-BB binding capability with the highest affinity found for normal palmar fascia decorin DS. In fibrosis affected palmar fascia DS/CS proteoglycans are able to form with PDGF-BB supramolecular complexes also including other matrix components such as type III collagen and fibronectin which bind the growth factor covalently. Our results suggest that DS chains of fascia matrix small PGs may regulate PDGF-BB availability leading to restriction of fibrosis associated with Dupuytren's disease or to control of normal fascia repair.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19631712     DOI: 10.1016/j.biochi.2009.07.010

Source DB:  PubMed          Journal:  Biochimie        ISSN: 0300-9084            Impact factor:   4.079


  7 in total

1.  Update on the role of molecular factors and fibroblasts in the pathogenesis of Dupuytren's disease.

Authors:  Massimiliano Tripoli; Adriana Cordova; Francesco Moschella
Journal:  J Cell Commun Signal       Date:  2016-06-07       Impact factor: 5.782

2.  Dermatan sulfate is a player in the transglutaminase 2 interaction network.

Authors:  Grzegorz Wisowski; Ewa M Koźma; Tomasz Bielecki; Adam Pudełko; Krystyna Olczyk
Journal:  PLoS One       Date:  2017-02-15       Impact factor: 3.240

Review 3.  The dual role of the glycosaminoglycan chondroitin-6-sulfate in the development, progression and metastasis of cancer.

Authors:  Adam Pudełko; Grzegorz Wisowski; Krystyna Olczyk; Ewa Maria Koźma
Journal:  FEBS J       Date:  2019-02-05       Impact factor: 5.542

4.  Propolis induces chondroitin/dermatan sulphate and hyaluronic Acid accumulation in the skin of burned wound.

Authors:  Pawel Olczyk; Katarzyna Komosinska-Vassev; Katarzyna Winsz-Szczotka; Jerzy Stojko; Katarzyna Klimek; Ewa M Kozma
Journal:  Evid Based Complement Alternat Med       Date:  2013-03-07       Impact factor: 2.629

5.  Iduronic acid in chondroitin/dermatan sulfate affects directional migration of aortic smooth muscle cells.

Authors:  Barbara Bartolini; Martin A Thelin; Lena Svensson; Giancarlo Ghiselli; Toin H van Kuppevelt; Anders Malmström; Marco Maccarana
Journal:  PLoS One       Date:  2013-07-02       Impact factor: 3.240

6.  Decorin mimic regulates platelet-derived growth factor and interferon-γ stimulation of vascular smooth muscle cells.

Authors:  Rebecca A Scott; Alyssa Panitch
Journal:  Biomacromolecules       Date:  2014-05-16       Impact factor: 6.988

7.  Complexation and sequestration of BMP-2 from an ECM mimetic hyaluronan gel for improved bone formation.

Authors:  Marta Kisiel; Agnieszka S Klar; Manuela Ventura; Jos Buijs; Marc-Krystelle Mafina; Simon M Cool; Jöns Hilborn
Journal:  PLoS One       Date:  2013-10-22       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.